DrugPatentWatch Database Preview
RITALIN LA Drug Profile
Which patents cover Ritalin La, and what generic alternatives are available?
Ritalin La is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.
This drug has one hundred and forty-two patent family members in thirty-three countries.
The generic ingredient in RITALIN LA is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
Summary for RITALIN LA
International Patents: | 142 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 2 |
Bulk Api Vendors: | 59 |
Clinical Trials: | 104 |
Patent Applications: | 4,106 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for RITALIN LA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RITALIN LA |
DailyMed Link: | RITALIN LA at DailyMed |

Pharmacology for RITALIN LA
Drug Class | Central Nervous System Stimulant |
Physiological Effect | Central Nervous System Stimulation |
Synonyms for RITALIN LA
113-45-1 (Parent) |
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester, hydrochloride |
2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride |
2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (R*,R*)-(+-)- |
298-59-9 |
298M599 |
AC1L1SQ4 |
AC1Q5YRN |
AK116471 |
AKOS016010356 |
alpha-phenyl-2-piperidineacetic acid methyl ester hydrochloride |
AN-23356 |
API0003340 |
CAS-298-59-9 |
CC-30903 |
CCG-213572 |
CCRIS 6258 |
Centedrin |
Centedrine |
CHEBI:31836 |
CHEMBL1722 |
ciba 4311b |
Concerta (TN) |
CS-4658 |
D-erythro-Methylphenidate Hydrochloride |
D01296 |
DSSTox_CID_886 |
DSSTox_GSID_20886 |
DSSTox_RID_75843 |
DTXSID8020886 |
EINECS 206-065-3 |
FT-0603372 |
FT-0672046 |
FT-0672047 |
H-Tic-OtBu.HCl |
HE332528 |
HY-B1091A |
JUMYIBMBTDDLNG-UHFFFAOYSA-N |
LS-42 |
Medikinet |
Meridil hydrochloride |
Metadate |
Metadate (TN) |
Metadate CD |
Metadate ER |
Methyl .alpha.-phenyl-2-piperidineacetate hydrochloride |
methyl 2-phenyl-2-(2-piperidyl)acetate hydrochloride |
METHYL 2-PHENYL-2-(PIPERIDIN-2-YL)ACETATE HCL |
Methyl 2-phenyl-2-(piperidin-2-yl)acetate hydrochloride |
methyl 2-phenyl-2-piperidin-2-ylacetate hydrochloride |
methyl alpha-phenyl-2-piperidine-acetate hydrochloride |
Methyl alpha-phenyl-2-piperidineacetate hydrochloride |
Methyl Phenidylacetate Hydrochloride |
methyl phenyl(piperidin-2-yl)acetate hydrochloride |
Methylin ER |
Methylphenidan Hydrochloride |
Methylphenidate (hydrochloride) |
Methylphenidate HCl |
METHYLPHENIDATE HYDROCHLORIDE |
Methylphenidate hydrochloride (JAN/USP) |
Methylphenidate hydrochloride [USAN:JAN] |
Methylphenidate hydrochloride [USP:JAN] |
Methylphenidate Hydrochloride ER |
Methylphenidate hydrochloride solution, (Racemic mixture), ampule of 1 mL, 1.0 mg/mL in methanol (as free base), certified reference material |
Methylphenidate hydrochloride, European Pharmacopoeia (EP) Reference Standard |
METHYLPHENIDATE HYDROCHLORIDE(SEE ALSO: METHYLPHENIDATE, CAS 113-45-1, NTPNO M20344) |
Methylphenidate.HCl |
Methylphenidate(Ritalin) |
Methylphenidylacetate hydrochloride |
Metilfenidat hydrochloride |
MFCD00058191 |
MLS003922100 |
NCGC00091942-01 |
NCGC00257863-01 |
NSC 169868 |
NSC-169868 |
NSC-759278 |
NSC169868 |
NSC759278 |
Pharmakon1600-01505907 |
QuilliChew ER |
Quillivant XR |
Quillivant xr (TN) |
Rilaline |
Rilatine |
Ritalin |
Ritalin (TN) |
Ritalin hy drochloride |
Ritalin hydrochloride |
Ritalin SR |
Ritalin-SR |
SC-83308 |
SCHEMBL41067 |
SMR000058998 |
threo-Methyl |A-phenyl-|A-(2-piperidyl)acetate hydrochloride |
Tox21_111186 |
Tox21_200309 |
TRANSGENIC MODEL EVALUATION (METHYLPHENIDATE HYDROCHLORIDE) (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE) |
WLN: T6MTJ BYR & VO1 & GH |
US Patents and Regulatory Information for RITALIN LA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-004 | Apr 10, 2004 | AB1 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-003 | Jun 5, 2002 | AB1 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-001 | Jun 5, 2002 | AB1 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-002 | Jun 5, 2002 | AB1 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for RITALIN LA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-004 | Apr 10, 2004 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-001 | Jun 5, 2002 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-002 | Jun 5, 2002 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-001 | Jun 5, 2002 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for RITALIN LA
Drugname | Dosage | Strength | RLD | Date |
---|---|---|---|---|
➤ Subscribe | Extended-release Capsules | 10 mg | ➤ Subscribe | ➤ Try a Free Trial |
➤ Subscribe | Extended-release Capsules | 20 mg, 30 mg and 40 mg | ➤ Subscribe | ➤ Try a Free Trial |
International Patents for RITALIN LA
Country | Document Number | Estimated Expiration |
---|---|---|
Singapore | 162811 | ➤ Try a Free Trial |
European Patent Office | 1905432 | ➤ Try a Free Trial |
World Intellectual Property Organization (WIPO) | 2006132752 | ➤ Try a Free Trial |
Israel | 142896 | ➤ Try a Free Trial |
Country | Document Number | Estimated Expiration |